Abstract
Recent progress in the treatment of multiple myeloma: updates and highlights from ASH 2008
Highlights
Current trends in leukemia, lymphoma, myeloma and ITP: updates and highlights from ASH 2008 Delong Liu Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1756-8722-2-S1-info.pdf
A series of large randomized trials have established the addition of a novel agent, either thalidomide or bortezomib, to melphalan and prednisone as the standard of care for transplant ineligible patients
Recent updates of 3 different studies, Italian study (GIMEMA), the Dutch study (HOVON 49) and the Scandinavian study showed improvement in progression-free survival but not OS. This may be related to differences in the dose intensity and tolerability of the treatment, lack of efficacy of thalidomide in high-risk cytogenetic group and availability of other novel agent to rescue upon relapse
Summary
Current trends in leukemia, lymphoma, myeloma and ITP: updates and highlights from ASH 2008 Delong Liu Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1756-8722-2-S1-info.pdf . Recent progress in the treatment of multiple myeloma: updates and highlights from ASH 2008 A series of large randomized trials have established the addition of a novel agent, either thalidomide or bortezomib, to melphalan and prednisone as the standard of care for transplant ineligible patients.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
